OnCo

Male breast cancer: lines of therapy

Cancer page →

4 standard-of-care settings across 3 lines and 3 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comersBRCA / HRDHR-positive
Early / localised1·1
Advanced, first line··1
Other settings·1·

Early / localised

SubgroupSettingApproachProducts and trialsEvidence
All comersEarly stageMastectomy (or breast conservation where feasible) with sentinel node biopsy; adjuvant radiotherapy by the same criteria as women; chemotherapy and HER2-directed therapy as indicated.89
HR-positiveAdjuvant endocrine, ER-positiveTamoxifen for five to ten years; aromatase inhibitor only with GnRH agonist suppression if tamoxifen is contraindicated.89

Advanced, first line

SubgroupSettingApproachProducts and trialsEvidence
HR-positiveAdvanced, ER-positiveEndocrine therapy (tamoxifen, or aromatase inhibitor or fulvestrant with GnRH agonist) with a CDK4/6 inhibitor by extrapolation; chemotherapy for visceral crisis.85

Other settings

SubgroupSettingApproachProducts and trialsEvidence
BRCA / HRDGermline BRCA carriersPARP inhibitor (olaparib adjuvant per OlympiA; olaparib or talazoparib for metastatic disease) and cascade testing of relatives.94

Sequence and caution pairings

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.